On April 21, 2026 Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, reported that new clinical data from its non-small cell lung cancer (NSCLC) pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29–June 2 in Chicago. The presentations will feature the company’s investigational assets ZEGFROVY (sunvozertinib), golidocitinib, and DZD6008, highlighted by two oral presentations, including one selected as a Late-Breaking Abstract (LBA).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Results from the multinational Phase 3 WU-KONG28 study of ZEGFROVY have been selected for oral presentation as an LBA. ZEGFROVY is an oral, irreversible, and highly selective EGFR tyrosine kinase inhibitor (TKI), approved in China and the U.S. for the treatment of relapsed or refractory NSCLC harboring EGFR exon20ins. WU-KONG28 is a phase 3 randomized pivotal study comparing sunvozertinib vs. chemo doublet in previously untreated NSCLC patients with EGFR exon20ins mutation. Earlier, Dizal announced that the study had met its primary endpoint with statistically significant and clinically meaningful improvement in progression-free survival (PFS).
Updated clinical data of DZD6008 in pretreated NSCLC patients with EGFR C797X mutations have also been selected for oral presentation. DZD6008 is a novel, highly selective fourth-generation EGFR TKI with full blood-brain barrier (BBB) penetration, designed to address clinical challenges after treatment failure from third-generation EGFR TKIs. In preclinical models, DZD6008 exhibits potent and consistent inhibitory activity across a broad range of EGFR mutations, including EGFR driver mutations (L858R and exon 19 deletions), resistant double mutations (including T790M/C797S in the context of L858R or exon 19 deletion), and the challenging triple mutations (C797X plus T790M plus L858R or exon 19 deletion).
In addition, Dizal will present the latest findings from a study evaluating golidocitinib in combination with anti–PD-1 antibody in NSCLC without known driver mutations. Golidocitinib is the world’s first and only approved JAK1 inhibitor for relapsed or refractory peripheral T-cell lymphoma. Preclinical data indicate that JAK inhibition can rescue exhausted T-cell function and modulate the tumor microenvironment, providing a mechanistic basis for the combination of golidocitinib with anti-PD-1/PD-L1 therapies in NSCLC patients who have progressed on prior anti-PD-1 containing regimens.
Dr. Xiaolin Zhang, CEO of Dizal, said: "The new data to be reported at ASCO (Free ASCO Whitepaper) 2026 show significant progress we have made with our non-small cell lung cancer (NSCLC) pipeline. We are especially happy to report that WU-KONG28 met its primary endpoint. EGFR exon20ins is a tough target, and several compounds have failed in clinical studies. With this positive study, Zegfrovy further demonstrates its potential as the treatment of choice for newly diagnosed lung cancer patients with EGFR exon20ins mutation."
Dizal presentation details during 2026 ASCO (Free ASCO Whitepaper):
Lead Author
Abstract Title
Presentation Details
Prof. John Heymach
Sunvozertinib monotherapy versus platinum-
based chemotherapy as first-line treatment for
advanced NSCLC with EGFR exon20ins:
Primary analysis of a multinational phase 3
randomized study (WU-KONG28)
Publication Number: LBA8500
Oral Abstract Session
May 29, 2026, 1:00 PM-4:00 PM
CDT
Prof. Mengzhao
Wang
DZD6008, a 4th Generation EGFR TKI, in
Pretreated NSCLC Patients with EGFR C797X
Mutations: Results from Phase 1/2 Studies
Publication Number: 8520
Rapid Oral Abstract Session
May 30, 2026, 1:15 PM-2:45 PM
CDT
Prof. Jie Wang
Combination of golidocitinib (a JAK1 inhibitor)
with anti–PD-1 antibody to improve tumor
response and patient quality of life: Preliminary
results from an ongoing JACKPOT 33 study
Publication Number: 8555
Poster Session
May 31, 2026, 9:00 AM-12:00
PM CDT
About ZEGFROVY(sunvozertinib)
ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The approval in China is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1 Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication.
In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations, as well as HER2 exon20ins.
ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.
WU-KONG28, a multinational, randomized Phase 3 study conducted across 16 countries and regions evaluating ZEGFROVY as first-line treatment for patients with EGFR exon20ins NSCLC, met its primary endpoint.
Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology.
About Golidocitinib (DZD4205)
Golidocitinib is currently the first and only Janus kinase 1 (JAK1) inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).
At the date of August 31, 2023, golidocitinib demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.
Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).
About DZD6008
DZD6008 is a novel, highly selective, full-BBB penetrant EGFR TKI, designed as a potential treatment option for advanced EGFR mutation positive (EGFRm) NSCLC.
Non-small cell lung cancer is the leading cause of cancer death in the world. Epidermal growth factor receptor (EGFR) gene is one of the most common driver genes for NSCLC. Multiple agents can be used to treat patients with EGFR mutated NSCLC who develop resistance to EGFR tyrosine kinase inhibitors (TKIs), but the clinical outcome was not satisfactory. Brain metastases (BM) are a leading cause of death and disease progression for NSCLC. Approximately 23%-30% of NSCLC patients are synchronous BM at their initial diagnosis. Previous studies reported that the 3-year cumulative rate of BMs ranges from 29.4% to 60.3% in patients with mutated EGFR.
Currently, the clinical benefits of existing treatments for third-generation EGFR TKI-resistant NSCLC are limited and DZD6008 is expected to fill the unmet medical needs. DZD6008 effectively inhibits EGFR-mutated tumor growth in cell lines and in animal models. Previous clinical studies have validated the design concept of the molecule and suggest that DZD6008 demonstrates good safety and efficacy in NSCLC patients with brain metastases who had failed third-generation EGFR TKI therapy or multiple lines of pre-treatments.
(Press release, Dizal Pharma, APR 21, 2026, View Source [SID1234664636])